Forte Biosciences (FBRX) Net Income Growth (1y) (2017 - 2026)
Forte Biosciences (FBRX) Net Income Growth (1y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,681.27 Bn | 66,680.98 Bn | - | -0.46% |
| 2 | Nanobiotix | 1,911.83 Bn | 1,911.77 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 472.75 Bn | 467.96 Bn | 1.35 Bn | 17,802.13% |
| 5 | Vertex Pharmaceuticals | 122.14 Bn | 114.89 Bn | 2.59 Bn | 59.59% |
| 6 | Regeneron Pharmaceuticals | 70.09 Bn | 61.34 Bn | 3.31 Bn | -10.08% |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.94 Bn | 50.76 Bn | 1.41 Bn | 63.48% |
| 9 | Alnylam Pharmaceuticals | 37.52 Bn | 34.51 Bn | 959.66 Mn | 1,228.66% |
| 10 | Forte Biosciences | 1.36 Bn | 1.31 Bn | - | -41.39% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -41.39% |
| Dec 31, 2025 | -231.19% |
| Sep 30, 2025 | -313.47% |
| Jun 30, 2025 | -91.56% |
| Mar 31, 2025 | -99.90% |
| Dec 31, 2024 | -15.93% |
| Sep 30, 2024 | 15.30% |
| Jun 30, 2024 | -40.85% |
| Mar 31, 2024 | -13.10% |
| Dec 31, 2023 | -28.12% |
| Sep 30, 2023 | -190.29% |
| Jun 30, 2023 | -181.69% |
| Mar 31, 2023 | -145.74% |
| Dec 31, 2022 | 61.16% |
| Sep 30, 2022 | 59.69% |
| Jun 30, 2022 | 88.80% |
| Mar 31, 2022 | 90.32% |
| Dec 31, 2021 | -25.44% |
| Sep 30, 2021 | 80.75% |
| Jun 30, 2021 | 31.29% |